Balanced news tone
News Sentiment
VTGN sentiment intelligence
VistaGen Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
42
Balanced news tone
53 relevant articles
News tone and price action are not far from neutral.
76/100 classification confidence.
directly relevant articles
high-authority source matches
+3.7% over one week, -55.2% over four weeks, trend inactive, and below fair value.
Is Vistagen Therapeutics, Inc. (VTGN) Stock Facing New Challenges After PALISADE-4 Clinical Trial Results?
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Primary event
Market update
76/100 classification
One-week reaction
3.7%
Price confirming higher
Trend fit
Trend inactive
-55.2% over four weeks
Fair value
-91.4%
Below fair value
Value support
Sentiment Mix
Positive, neutral, negative
Positive
2
Neutral
35
Negative
16
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Market source
Industry context
Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 16 Jul 2026 18:49
- Source
- Market source
Market source
Direct company coverage
Is Vistagen Therapeutics, Inc. (VTGN) Stock Facing New Challenges After PALISADE-4 Clinical Trial Results?
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 15 Jul 2026 09:22
- Source
- Market source
Market source
Industry context
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Jul 2026 12:30
- Source
- Market source
Stocktwits
Direct company coverage
This Stock Lost 71% Of Value After Anxiety Therapy Missed Key Goals – But Retail Believes It’s Oversold, Says Won’t Panic-Sell
Shares of Vistagen (VTGN) plummeted over 71% after its anxiety therapy, Fasedienol, failed to meet primary and secondary endpoints in a late-stage trial. Despite the setback and the treatment showing no significant difference from placebo, the company plans to discuss a potential
- Tone
- Negative 13/100
- Event
- Market update
- Published
- 11 Jul 2026 14:11
- Source
- Stocktwits
Investing.com Nigeria
Direct company coverage
Form 4 VistaGen Therapeutics Inc For: 2 July By Investing.com
This article reports on a Form 4 filing for VistaGen Therapeutics Inc. on July 2 with Investing.com as the source. It concisely conveys the release of this financial disclosure.
- Tone
- Negative 40/100
- Event
- Market update
- Published
- 07 Jul 2026 00:09
- Source
- Investing.com Nigeria
Moomoo
Direct company coverage
Stifel Maintains VistaGen Therapeutics(VTGN.US) With Hold Rating, Maintains Target Price $1
Stifel has reiterated its Hold rating on VistaGen Therapeutics (VTGN.US) and maintained its price target of $1.00. This suggests the firm's continued neutral stance on the stock, with an expectation that its value will remain around the current target.
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 06 Jul 2026 11:10
- Source
- Moomoo
Finviz
Direct company coverage
VTGN - Vistagen Therapeutics Inc Latest SEC Filings
This article provides the latest SEC filings information for Vistagen Therapeutics Inc (VTGN), along with comprehensive financial data, stock performance metrics, and analyst recommendations. It details key figures such as market capitalization, income, sales, EPS, and various fi
- Tone
- Negative 29/100
- Event
- Earnings
- Published
- 04 Jul 2026 02:40
- Source
- Finviz
TradingView
Direct company coverage
Price to sales forward of Vistagen Therapeutics, Inc. – NASDAQ:VTGN
This article provides financial information for Vistagen Therapeutics, Inc. (NASDAQ: VTGN), specifically focusing on its price to sales forward metric. It appears to be a stub or an incomplete financial data page from TradingView, showing no specific data values but indicating th
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 03 Jul 2026 21:09
- Source
- TradingView
TradingView
Direct company coverage
Enterprise value to revenue forward of Vistagen Therapeutics, Inc. – NASDAQ:VTGN
The article references the "Enterprise value to revenue forward" metric for Vistagen Therapeutics, Inc. (NASDAQ: VTGN) on the TradingView platform. It provides some basic stock market information for VTGN, including its NASDAQ listing and current market status. The content appear
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 03 Jul 2026 11:40
- Source
- TradingView
TradingView
Direct company coverage
Price to book forward of Vistagen Therapeutics, Inc. – NASDAQ:VTGN
The article displays the "Price to book forward" financial metric for Vistagen Therapeutics, Inc. (NASDAQ: VTGN) on the TradingView platform. It presents a simple table showing the period, value, change, and percentage change for this specific financial indicator. The content is
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 03 Jul 2026 04:10
- Source
- TradingView
Stock Titan
Direct company coverage
Vistagen (VTGN) CEO adds 36,818 ESPP shares, now holds over 54,000 directly
Vistagen Therapeutics, Inc. President and CEO Shawn Singh acquired 36,818 shares of common stock through the company's Employee Stock Purchase Plan at $0.1921 per share. This acquisition, exempt under Rule 16b-3, increases his direct holdings to 54,846 shares. Additionally, 20,87
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 02 Jul 2026 20:10
- Source
- Stock Titan
Stock Titan
Direct company coverage
Vistagen (VTGN) Chief Legal Officer adds 36,818 ESPP shares in Form 4 filing
Vistagen Therapeutics' Chief Legal Officer, Reid G. Adler, increased his holdings by acquiring 36,818 shares of common stock through the company's 2019 Employee Stock Purchase Plan. This transaction, executed on June 30, 2026, at an average price of $0.1921 per share, was exempt
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jul 2026 20:10
- Source
- Stock Titan
Stock Titan
Direct company coverage
ESPP grant gives Vistagen (NASDAQ: VTGN) CFO 11,712 new shares
Vistagen Therapeutics, Inc.'s Chief Financial Officer, Nick B. Tressler, acquired 11,712 shares of common stock on June 30, 2026, through the company’s 2019 Employee Stock Purchase Plan at $0.1921 per share. Following this transaction, his direct holdings amount to 11,712 shares,
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jul 2026 20:10
- Source
- Stock Titan
Market source
Direct company coverage
Vistagen Announces Topline and Post-Hoc Data from PALISADE-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety Disorder
Vistagen announced topline results from its PALISADE-4 Phase 3 trial for fasedienol, which did not meet primary or secondary endpoints for treating social anxiety disorder in the overall population. However, a post-hoc analysis showed statistically significant improvement in pati
- Tone
- Negative 35/100
- Event
- Earnings
- Published
- 01 Jul 2026 22:39
- Source
- Market source
AllSci
Direct company coverage
Vistagen’s fasedienol fails second Phase III social anxiety trial, clouding acute treatment strategy
Vistagen Therapeutics announced that its fasedienol candidate failed a second Phase III trial (PALISADE-4) for social anxiety disorder, again missing its primary endpoint. This result puts pressure on the company to identify a credible path forward with the FDA, especially as the
- Tone
- Negative 9/100
- Event
- Market update
- Published
- 01 Jul 2026 09:41
- Source
- AllSci
The National Law Review
Direct company coverage
Bronstein, Gewirtz & Grossman, LLC Is Investigating Vistagen Therapeutics, Inc. (VTGN) And Encourages Investors to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Vistagen Therapeutics, Inc. (VTGN) on behalf of investors who purchased securities prior to April 1, 2024, and still hold them. The investigation aims to determine if Vistagen's officers and/or directors
- Tone
- Negative 28/100
- Event
- Regulatory and legal
- Published
- 01 Jul 2026 07:39
- Source
- The National Law Review
Benzinga
Direct company coverage
Penny Stock Vistagen Keeps Regulatory Plans Alive Despite Anxiety Study Miss
Vistagen Therapeutics' Phase 3 PALISADE-4 trial for its intranasal fasedienol in acute social anxiety disorder missed its primary and secondary endpoints. However, a post-hoc analysis identified a statistically significant benefit in patients with very severe social anxiety, prom
- Tone
- Negative 15/100
- Event
- Regulatory and legal
- Published
- 30 Jun 2026 17:10
- Source
- Benzinga
Bitget
Direct company coverage
VistaGen Therapeutics, Inc. (VTGN) announced topline data and post-hoc analysis results from the Phase 3 clinical trial Palisade-4 of its candidate drug Fasedienol for the acute treatment of social anxiety disorder.
VistaGen Therapeutics (VTGN) released topline data and post-hoc analysis results from its Phase 3 Palisade-4 trial for Fasedienol, a drug for acute social anxiety disorder. The trial, using a public speaking challenge model, did not show a statistically significant difference bet
- Tone
- Negative 40/100
- Event
- Earnings
- Published
- 30 Jun 2026 14:39
- Source
- Bitget
Stock Titan
Direct company coverage
Vistagen (NASDAQ: VTGN) Phase 3 fasedienol trial misses main goal but shows severe-SAD signal
Vistagen's Phase 3 PALISADE-4 trial for intranasal fasedienol in social anxiety disorder (SAD) missed its primary and secondary endpoints in the overall patient population. However, a post-hoc analysis revealed a nominally statistically significant improvement in a subgroup of pa
- Tone
- Negative 40/100
- Event
- Market update
- Published
- 30 Jun 2026 12:10
- Source
- Stock Titan
TradingView
Direct company coverage
Vistagen reports PALISADE-4 miss on primary endpoints; positive post-hoc signal in very severe SAD subgroup
Vistagen (VTGN) announced that its PALISADE-4 trial did not meet its primary or secondary endpoints for social anxiety disorder (SAD). However, a post-hoc analysis revealed a nominally significant benefit in a subgroup of patients with very severe SAD. The company plans to engage
- Tone
- Negative 37/100
- Event
- Market update
- Published
- 30 Jun 2026 12:10
- Source
- TradingView
Fierce Biotech
Direct company coverage
Vistagen fails another phase 3 anxiety trial, spies path forward
Vistagen's social anxiety disorder drug candidate, fasedienol, has failed another phase 3 trial, PALISADE-4, missing its primary and secondary endpoints. Despite the setback, the company plans to pursue FDA approval by leveraging post hoc analysis data from a subpopulation of pat
- Tone
- Negative 5/100
- Event
- Regulatory and legal
- Published
- 30 Jun 2026 09:48
- Source
- Fierce Biotech
Stock Titan
Direct company coverage
Vistagen’s fasedienol fails main test, but one subgroup showed a signal
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 30 Jun 2026 07:00
- Source
- Stock Titan
TradingView
Direct company coverage
Vistagen Therapeutics, Inc. Actuals & Estimates (NASDAQ:VTGN)
This article provides an overview of Vistagen Therapeutics, Inc. (VTGN) financial actuals and analyst estimates, including its current stock price, market capitalization, and historical performance. It also details quarterly earnings, revenue, and future earnings report dates. Th
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 26 Jun 2026 17:40
- Source
- TradingView
TradingView
Direct company coverage
Vistagen Therapeutics, Inc. Actuals & Estimates (BOATS:VTGN)
This article provides financial actuals and estimates for Vistagen Therapeutics, Inc. (VTGN) on the BOATS exchange, including analyst forecasts, historical price data, and upcoming earnings information. It details the company's financial performance, such as recent earnings and r
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 26 Jun 2026 05:39
- Source
- TradingView
TradingView
Direct company coverage
VTGN Forecast — Price Target — Prediction for 2027
This article provides a forecast for Vistagen Therapeutics, Inc. (VTGN) stock, including analyst price targets and ratings. It details current stock performance, historical highs and lows, volatility, market capitalization, and upcoming earnings information. The report also addre
- Tone
- Negative 38/100
- Event
- Analyst action
- Published
- 25 Jun 2026 19:10
- Source
- TradingView
The Globe and Mail
Direct company coverage
Vistagen Therapeutics’ 2026 Workforce Cuts Raise Execution Risks and Threaten Long-Term Growth
Vistagen Therapeutics Inc. is facing increased execution risks due to its planned March 2026 workforce reduction, which aimed to conserve cash and advance trials for fasedienol. This downsizing could lead to a loss of institutional knowledge, lower employee morale, and hinder the
- Tone
- Negative 29/100
- Event
- Balance sheet
- Published
- 19 Jun 2026 03:09
- Source
- The Globe and Mail
Investing.com
Direct company coverage
Vistagen Therapeutics directors to step down after 2026 annual meeting
Vistagen Therapeutics announced that two board members, Margaret FitzPatrick and Dr. Joanne Curley, will not seek re-election at the company’s 2026 Annual Meeting of Stockholders. Both will continue to serve until their terms conclude at the meeting. This news follows a period of
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 02:39
- Source
- Investing.com
Sahm
Direct company coverage
Here's Why Vistagen Therapeutics (NASDAQ:VTGN) Must Use Its Cash Wisely
Vistagen Therapeutics (NASDAQ:VTGN) is burning through cash at a concerning rate, with a cash burn of US$61m against US$45m in reserves as of March 2026, giving it only about 9 months of cash runway. The company's cash burn increased by 43% last year, and its cash burn relative t
- Tone
- Negative 20/100
- Event
- Balance sheet
- Published
- 18 Jun 2026 02:39
- Source
- Sahm
TradingKey
Direct company coverage
Vistagen Therapeutics Inc (VTGN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article from TradingKey provides a revenue breakdown for Vistagen Therapeutics Inc (VTGN). It notes that relevant data regarding the company's business segments, regional revenue, and profit contribution have not yet been disclosed by the company. The page also presents curr
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 18 Jun 2026 01:00
- Source
- TradingKey
Stock Titan
Direct company coverage
Two Vistagen (VTGN) directors will not seek re-election at 2026 shareholder meeting
Vistagen Therapeutics, Inc. announced that two of its board members, Margaret FitzPatrick and Dr. Joanne Curley, will not seek re-election at the company's 2026 Annual Meeting of Stockholders. Both directors will continue to serve until their current terms conclude at the meeting
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Jun 2026 21:40
- Source
- Stock Titan